Can you explain the immune mechanisms of the four types of hypersensitivity reactions and provide veterinary medicine examples for each?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

The Four Types of Hypersensitivity Reactions: Immune Mechanisms and Veterinary Examples

The Gell and Coombs classification divides hypersensitivity reactions into four distinct types based on their underlying immune mechanisms: Type I (IgE-mediated), Type II (antibody-mediated cytotoxic), Type III (immune complex-mediated), and Type IV (T cell-mediated delayed responses). 1

Type I Hypersensitivity: IgE-Mediated Reactions

Immune Mechanism

Type I reactions involve IgE antibodies binding to high-affinity IgE receptors (FcεRI) on mast cells and basophils. Upon re-exposure to the allergen, cross-linking of IgE triggers immediate degranulation of these cells, releasing histamine, leukotrienes, prostaglandins, and other inflammatory mediators within minutes to hours 1, 2. Additional cells including neutrophils, monocytes, macrophages, and platelets may participate through complement components, cysteinyl leukotrienes, platelet activating factor, IL-6, IL-10, and TNF-receptor 1 2.

Clinical Manifestations

These reactions manifest as anaphylaxis, urticaria, angioedema, bronchospasm, and acute allergic responses 1. Symptoms include hives, pruritus, respiratory compromise (dyspnea, wheezing, stridor), hypotension, gastrointestinal signs (vomiting, diarrhea), and cardiovascular collapse 1.

Veterinary Examples

In dogs, vaccines are the most frequent trigger for anaphylaxis (57.9% of cases) and mild hypersensitivity reactions (28.4%) 3. The estimated incidence is 0.04% for anaphylaxis and 0.15% for mild hypersensitivity reactions in dogs 3. Notably, 57.9% of dogs with anaphylaxis had no cutaneous signs reported, challenging the assumption that skin manifestations are always present 3. Female dogs have a significantly higher risk (female:male ratio of 2.3:1) 3.

Other veterinary examples include:

  • Insect sting hypersensitivity in horses and dogs
  • Food allergies in dogs and cats
  • Drug reactions to antibiotics (particularly beta-lactams) in various species
  • Atopic dermatitis in dogs, which involves IgE-mediated responses to environmental allergens 4

Type II Hypersensitivity: Antibody-Mediated Cytotoxic Reactions

Immune Mechanism

Type II reactions involve IgG or IgM antibodies directed against cell surface or extracellular matrix antigens. These antibodies bind to target cells and trigger destruction through three mechanisms: complement-mediated lysis, antibody-dependent cellular cytotoxicity (ADCC), or antibody-mediated cellular dysfunction 1, 5.

Clinical Manifestations

The hallmark presentations include hemolytic anemia, thrombocytopenia, neutropenia, and blood transfusion reactions 1. Tissue damage occurs at the site where antibodies bind to cellular antigens.

Veterinary Examples

Immune-mediated hemolytic anemia (IMHA) in dogs is a classic Type II reaction where antibodies target red blood cell surface antigens, leading to hemolysis. This can be primary (idiopathic) or secondary to drugs, infections, or neoplasia.

Other veterinary examples include:

  • Immune-mediated thrombocytopenia (ITP) in dogs and cats
  • Neonatal isoerythrolysis in foals and kittens (when maternal antibodies attack neonatal red blood cells)
  • Drug-induced hemolytic anemia (e.g., from cephalosporins, penicillins)
  • Blood transfusion reactions in all species when incompatible blood types are administered

Type III Hypersensitivity: Immune Complex-Mediated Reactions

Immune Mechanism

Type III reactions occur when antigen-antibody complexes (immune complexes) deposit in tissues, particularly blood vessel walls. These complexes activate complement, which recruits neutrophils and other inflammatory cells. The neutrophils release proteolytic enzymes and reactive oxygen species, causing local tissue damage and inflammation 1, 5.

Clinical Manifestations

Clinical presentations include serum sickness, vasculitis, glomerulonephritis, and arthritis 1. The reaction typically develops 7-21 days after antigen exposure, corresponding to the time needed for antibody production and immune complex formation.

Veterinary Examples

Two critically ill dogs developed leukocytoclastic vasculitis 8-16 days after administration of human serum albumin (HSA), with histopathology showing epidermal pallor, widespread edema and hemorrhage, degenerative neutrophilic perivascular infiltrates, and multifocal neutrophilic vasculitis 6. Immunohistochemical staining confirmed antigen-antibody complexes containing HSA in the dermis 6.

Other veterinary examples include:

  • Serum sickness in horses following administration of heterologous antisera (e.g., tetanus antitoxin)
  • Glomerulonephritis in dogs secondary to chronic infections or immune complex deposition
  • Purpura hemorrhagica in horses (immune-mediated vasculitis following Streptococcus equi infection)
  • Vaccine-associated vasculitis in various species

Type IV Hypersensitivity: T Cell-Mediated Delayed Reactions

Immune Mechanism

Type IV reactions are mediated by sensitized T lymphocytes rather than antibodies, with onset typically 24-72 hours after antigen exposure. Modern understanding recognizes four subtypes 7:

  • Type IVa: Th1 cells and monocytes produce IFN-γ, IL-1, and IL-2
  • Type IVb: Th2 cells and eosinophils produce IL-4, IL-5, and IL-13
  • Type IVc: CD8+ cytotoxic T cells release perforin, granzyme B, and Fas ligand
  • Type IVd: CD4+/CD8+ T cells and neutrophils produce IL-8 and GM-CSF

Clinical Manifestations

Type IV reactions present as allergic contact dermatitis, tuberculin-type reactions, granulomatous inflammation, and various drug eruptions including maculopapular exanthema, Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis 1, 7.

Veterinary Examples

Allergic contact dermatitis in dogs and cats from exposure to plants (poison ivy), metals (nickel in collars), topical medications, or cleaning products represents the classic Type IV reaction in veterinary medicine.

Other veterinary examples include:

  • Tuberculin skin testing reactions in cattle (diagnostic test for tuberculosis)
  • Flea allergy dermatitis in dogs and cats (involves both Type I and Type IV mechanisms, with Type IV contributing to chronic inflammation)
  • Drug eruptions in horses from topical or systemic medications
  • Granulomatous reactions to foreign bodies or infectious agents in all species
  • Chronic allergic rhinitis and asthma in horses (Type IVb mechanism) 7

Critical Clinical Considerations

Important caveats: Not all hypersensitivity reactions fit neatly into one category—many clinical conditions involve overlapping mechanisms 7, 8. For example, flea allergy dermatitis involves both immediate Type I mast cell degranulation and delayed Type IV T cell responses.

Regarding treatment in veterinary medicine: The retrospective study of 86 dogs with hypersensitivity reactions found that glucocorticoid use was not associated with clinical improvement or survival 3. This challenges routine glucocorticoid administration for mild Type I reactions in dogs, though epinephrine remains the cornerstone for anaphylaxis management 2, 3.

Biphasic reactions: Anaphylaxis can recur 1-72 hours after initial resolution, occurring in <1% to 20% of patients, with higher risk in those presenting with severe initial symptoms 2. Observation periods should be individualized based on reaction severity and proximity to emergency care 1.

Human serum albumin administration in critically ill dogs carries risk of Type III hypersensitivity, previously documented only in healthy dogs 6. Clinicians should monitor for vasculitis development 8-16 days post-administration.

Related Questions

Which antibiotics are associated with allergic-type throat pruritus progressing to cough, and what interventions are recommended?
What are the differences between Type I (IgE‑mediated) hypersensitivity, Type II (tissue‑specific) hypersensitivity, Type III (immune‑complex‑mediated) hypersensitivity, and Type IV (cell‑mediated) hypersensitivity?
Which antibiotics are known to cause adverse respiratory reactions such as wheezing, bronchospasm, cough, or dyspnea?
What is the appropriate management for an IgG-mediated drug hypersensitivity rash?
What is an appropriate antibiotic prophylaxis for a patient with an IgE-mediated response to Augmentin (amoxicillin-clavulanate)?
In a patient who fell from a wheelchair during a seizure yesterday, is currently stable, and did not sustain head trauma while already on seizure precautions, should neurochecks be initiated?
How should an adult patient with an arterial pH of 7.3 due to metabolic acidosis be managed?
How should a 47‑year‑old woman with anemia (Hb 7.9 g/dL), elevated ESR, uremia (urea 88 mg/dL, creatinine 5.7 mg/dL), hyperkalaemia (potassium 6 mmol/L), borderline TSH (4.44 µIU/mL) and vitamin D deficiency (19 ng/mL) be managed?
What is the recommended antibiotic regimen for mastoiditis, including dosing, duration, and alternatives for penicillin allergy or MRSA?
Does duloxetine affect hepatic enzyme activity?
What is the appropriate renal dosing of cephalexin (Keflex) 500 mg for a patient on hemodialysis with a creatinine clearance of 16 mL/min, who receives dialysis on Tuesday, Thursday, and Saturday?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.